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"Women are not dying of diseases we can't treat. They are dying because societies have yet to 
make the decision that their lives are worth saving."   
- Mahmoud Fathalla 
 
 
 
ABSTRACT 
Background: Retained placenta is associated with severe postpartum hemorrhage but its etiology and 
pathophysiology are largely unknown. Certain studies have suggested that retained placenta is associated 
to defective placentation disorders- pregnancy disorders with an initial defective placentation resulting in 
increased oxidative stress. The aim of this thesis was to investigate risk factors for and consequences of 
retained placenta, determine whether retained placenta and defective placentation disorders are 
epidemiologically associated and to assess if this association is supported at the molecular and 
histological level.  
Methods and Main Results: Study I was a case-control study comparing pregnancy and delivery-
related variables in women with retained placenta and controls (n=408 in each group) after singleton 
vaginal birth. The study found that retained placenta was associated with severe postpartum hemorrhage 
and that a history of abortion or recurrent miscarriage, pre-eclampsia, preterm delivery and prolonged 
oxytocin use in the current pregnancy were independent risk factors for retained placenta. Study II was a 
population based cohort study investigating the association between retained placenta and defective 
placentation disorders (pre-eclampsia, preterm birth, small-for-gestational-age birth and stillbirth) in 
primiparous women giving vaginal birth at 32-41 gestational weeks between 1997 and 2009 in Sweden 
(n=386 607). The study found that retained placenta was associated to pre-eclampsia, spontaneous 
preterm birth, small-for-gestational-age birth and stillbirth. The risk was further increased for women 
with these disorders among preterm deliveries. Study III was a cross-sectional pilot study investigating 
the antioxidative enzyme Glutathione Peroxidase 1 (GPX1) and the transcription factor Nuclear Factor 
Kappa-light-chain-enhancer of activated β-cells (NFκB), as markers of antioxidative defence capacity 
and inflammation, in 29 retained and 31 non-retained placentas. The study found that retained placentas 
showed a tendency of lower median concentrations GPX1 and were significantly more likely to have a 
low level of GPX1 protein concentration. There were no differences in expression of NFκB. Study IV 
was a case-control study comparing histological signs of maternal underperfusion and inflammation in 
retained (n=49) and non-retained (n=47) placentas. The study found that retained placentas had a 
significantly smaller surface area, were more oblong in shape and showed overall more signs of maternal 
placental underperfusion compared to non-retained placentas. 
Conclusions: Retained placenta is epidemiologically associated to defective placentation disorders, a 
finding which is supported in part by signs of decreased antioxidative capacity in the placenta and 
increased histological signs of maternal placental underperfusion. Prolonged oxytocin use may 
exacerbate the risk of retained placenta. Risk awareness of retained placenta should guide preparedness 
during the third stage of labor given the high risk of severe postpartum hemorrhage that the disorder 
entails. 
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1 INTRODUCTION AND RATIONALE 
Retained placenta is globally a major cause of severe postpartum hemorrhage and in areas 
without access to advanced obstetric care it is often fatal1. Despite this, its etiology is unknown 
and there is no preventative or non-invasive treatment2. What motivated this research project 
was the severity of the consequences of retained placenta in a context lacking research. There 
existed a need to identify clear risk factors and investigate whether there were biochemical and 
structural properties characteristic to this poorly understood disorder.  
A 2-3% incidence potentially means that millions of women suffer severe postpartum 
hemorrhage as a result of retained placenta every year1. The treatment, manual removal of the 
placenta, is an invasive procedure involving an increased risk of infection, the risks of full 
anesthesia as well as the immediate separation of mother and child after delivery3. There is no 
pharmacological treatment for retained placenta that has proved to decrease the need of manual 
removal of the placenta2. 
At the start of this research project twenty years had passed since the risks associated to retained 
placenta were analyzed in a large study group in a modern obstetric context4. Since then the 
average woman giving birth is older, heavier, more likely to use assisted reproductive 
technology, to have a history of previous cesarean section and to give birth with epidural 
anesthesia after prolonged and augmented labor5. Few pathological determinants for retained 
placenta were known and it was unknown whether these determinants were there at placentation 
or occurred after delivery. There were no studies investigating whether there were properties 
specific to retained placenta that would suggest that the disorder was related to other 
placentation disorders.  
The rationale for this project was firstly that knowledge of risk factors for retained placenta 
could help in identifying women at increased risk of serious hemorrhage, allow clinicians to act 
rapidly when the condition arises and to take preparatory measures if a high degree of risk is 
suspected; secondly that exploring the pathophysiology of this poorly understood condition, and 
its relationship to other pregnancy-related diseases, could be instrumental in its eventual 
prevention or in its less invasive treatment. This would be of importance most of all to the 
world´s most vulnerable obstetric population, women giving birth in low resource and poorly 
staffed settings. 
 2 
2 BACKGROUND 
 RETAINED PLACENTA DEFINED 
The timing of manual removal of a non-detached placenta differs globally6. The World Health 
Organization recommends that retained placenta be diagnosed if the placenta has not detached 
30 minutes after birth but, weighing the chance of spontaneous delivery against the increasing 
risk of hemorrhage with delay, recommends manual removal after a further 30 minutes if there 
are no signs of excessive hemorrhage prior to this7.   
Retained placenta can be separated into three subcategories based on clinical presentation: 
firstly placentas that are adherent to but can be manually separated from the uterine wall; 
secondly rare cases that display abnormal invasion into the uterine wall (placenta accreta); and 
thirdly placentas that are trapped behind a cervix that has contracted after delivery. This thesis is 
concerned with the first category, the adherent placenta, which is probably the most common 
form of retained placenta, representing approximately 80% of cases1. We have consequently, in 
addition to its diagnostic code, defined retained placenta by the surgical code for manual 
removal of the placenta (Study I and II), which although not excluding the entrapped placenta 
may reduce its proportional contribution; or by the actual verification during surgery of an 
adherent plane between the placenta and the uterine wall (Study III and IV). In Study III and 
IV all cases of retained placenta that reached the operating theatre were however found to be 
adherent obviating the need to exclude any that were entrapped. A recent Cochrane report found 
that continuous traction of the umbilical cord to detach the placenta after birth, as is routinely 
performed at the hospital where our studies were performed, reduces the need of manual 
removal of the placenta, possibly most so in cases where the placenta is trapped behind the 
cervix8.   
 CONSEQUENCES OF RETAINED PLACENTA 
The main complication to retained placenta is postpartum hemorrhage (blood loss >500ml) and 
severe postpartum hemorrhage (blood loss >1000ml)4,9,10. Untreated the fatality rate is 
somewhere between 2 and 10%1. A review of cases of retained placenta in Nigeria reported a 
fatality rate of 1.8%11. Many estimates from clinical settings however do not include deaths in 
areas where women deliver in less equipped facilities or do not reach health care facilities 
altogether. In a retrospective study of maternal deaths in rural Tanzania, 70% of which 
delivered at home, retained placenta accounted for the majority of all deaths12.  
 3 
 
Manual removal of the placenta furthermore increases the risk of postpartum endometritis 
threefold after adjusting for other sources of infection3,13. The procedure is often done under 
general anesthesia which in the immediate postpartum period is complicated by an increased 
risk of hypoxia and aspiration during intubation14.  
 RETAINED PLACENTA IN A HISTORICAL PERSPECTIVE 
2.3.1 Obstetric practice 
In the first decades of the 20th century obstetricians might wait several days for a retained 
placenta to detach in order to avoid the complications believed to result from manual 
removal15,16. This procedure, with a fatality rate of 10%, was considered one of the most deadly 
obstetric interventions17. Puerperal sepsis due to manual removal may have been as high as 60% 
at the beginning of the 20th century18. In hindsight the high death rate was most probably a result 
of the delay itself, with manual removal performed on women who were hypovolemic and 
septic due to severe blood loss, uterine atony and bacteremia19. Since bleeding in many cases of 
retained placenta is retroplacental, it may show first upon manual removal of the placenta 
leading clinicians to conclude that it was safe to wait. Until the 1950s obstetricians were not in 
agreement as to what the best practice was20. Since then the consensus is to remove the placenta 
if it has not detached within 30-60 minutes of the birth of the infant or if blood loss is 
excessive21.  
2.3.2 Increasing incidence  
There is a fairly strong consensus that the incidence of postpartum hemorrhage is increasing and 
that this increase cannot fully be accounted for by changes in demographic or delivery-related 
factors22-24. It is a little less clear whether the incidence of retained placenta is increasing. A 
historical analysis of national medical archives showed an increase in incidence across nine 
UK hospitals from 0.7% in 1920 to 2.3% in 198025. However, the rate increase between 1950, 
when the indications for manual removal may have become more standardized, and 1980 was 
more inconsistent. A study of 17 002 deliveries in a UK hospital 1947-1951 reported an 
incidence of 2.3%, very similar to today20. Another descriptive study from 1952 showed an 
incidence of manual removal of the placenta of 3.5% among 12 000 vaginal deliveries in a 
Harlem hospital26. Whether the reported rising incidence in the past century reflects a true 
increase or merely more consistency in diagnosis is uncertain.  
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 RETAINED PLACENTA IN A GLOBAL PERSPECTIVE 
Inconsistencies in the definition of retained placenta and recording of causes of maternal 
morbidity and mortality complicate the analysis of global disparities and changes in incidence 
of retained placenta. It has been suggested that retained placenta is less common in developing 
countries. A trend of rising incidence from low- to middle- to high-income countries would 
seem to support this1,27. The question is if this disparity is due to differences in obstetric 
practice, to demographic risk factors or to genetic variations. Interestingly a descriptive study of 
152 cases of retained placenta in Louisiana, USA, in 1941 noted that although black women 
made up 61% of the patient population they only made up 36% of cases of retained placenta28. 
A protective effect of non-white race has also been noted in a recent study29. 
Irrespective of incidence variations the consequences of retained placenta and hemorrhage are 
beyond doubt more severe in low resource settings. Postpartum hemorrhage causes a third of all 
maternal deaths worldwide and 99.6% of these deaths occur in low and middle income 
countries30. In Sweden only one woman died as a results of postpartum hemorrhage in the time 
span 1997-2005 which bluntly illustrates the global inequality in access to obstetric emergency 
care31. Uterine atony is the most common cause of postpartum hemorrhage but hemorrhage due 
to retained placenta may account for a greater proportion of severe hemorrhage and maternal 
death9,32,33. In other words, in a setting without access to skilled obstetric care, retained placenta 
may be a more dangerous cause of postpartum hemorrhage than uterine atony.  
 NORMAL AND ABNORMAL PLACENTATION 
In expectation of the implantation of the embryo, endometrial stromal cells normally transform 
into decidual cells (decidualization), of which some will become the basal decidua and of which 
some will surround the embryo, fuse with the smooth chorion and become part of the fetal 
membranes34. Around gestational day 12, extravillous trophoblasts from the developing embryo 
invade the basal decidua into the superficial myometrium and remodel the normally muscular 
uterine radial arteries into pliant spiral arteries34. This enables the low pressure vascular system 
needed to ensure blood follow to the developing fetus. Pregnancies that develop pre-eclampsia 
or end in miscarriage, preterm delivery or small-for-gestational-age (SGA) birth are more likely 
to show decreased spiral artery remodeling and a more shallow placentation35 (Figure 1). 
In cases of placenta accreta the placental villi are found in direct contact with the myometrium 
in areas where the decidua is absent. Trophoblast invasion then extends deeper into the 
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myometrium sometimes penetrating the entire uterine wall (placenta increta and percreta). It is 
debated whether this is due to increased invasive properties of the extravillous trophoblasts or to 
defective decidualization resulting in a poor implantation site which then requires deeper 
attachment36. In support of the latter theory the risk of placenta accreta increases if placental 
attachment occurs over an area with poor decidualization. The risk of accreta is thus increased 
with implantation in a previously irradiated uterus, implantation in the lower uterine segment 
(placenta previa), implantation over a previous uterine scar or implantation after previous 
dilatation and curettage (D&C), an intervention used to evacuate early pregnancy36. 
Figure 1 
Normal and abnormal placentation and spiral artery remodeling 
 
Printed with permission from the publisher. 
 6 
  NORMAL PLACENTAL RELEASE 
In clinical practice retained placenta is only diagnosed after vaginal birth. The average time till 
placental expulsion is between 6 and 10 minutes according to studies spanning over the past 70 
years and approximately 80% of placentas will have detached within 15 minutes of the birth of 
the infant4,20,37,38. After 30 minutes only 3.3% remained attached in an analysis of almost 13000 
deliveries between 1978 and 1988 but this included those that went on to need manual removal 
of the placenta4. In our analysis of 408 deliveries with spontaneous placental release, of which 
398 had data on time till placental expulsion, five percent were retained at 30 minutes, and only 
one percent at 43 minutes (Figure 2). In 1949 it was demonstrated radiographically that 
placental detachment requires continued uterine contractions after delivery20. Ultrasound studies 
have since then showed that normal placental separation occurs after a complete cessation of 
blood flow between the placenta and the myometrium followed by an isolated retroplacental 
myometrial contraction39,40. In a normal third stage there is a gradual thinning of the 
myometrium in the lower uterine segment and a myometrial thickening of the upper uterine 
segment which occurs in a linear fashion over time. In a third stage where placental release is 
relatively delayed (>12 minutes) but ultimately spontaneous, the thickness of the myometrium 
is reduced overall and the rate of change in each segment slower38. 
 
 
 
 
 
 
 
 
 
F
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Duration till placental expulsion (minutes) 
Figure 2 
Histogram of duration till placental expulsion among spontaneously detached placentas (n=398) 
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 PATHOPHYSIOLOGY OF RETAINED PLACENTA 
2.7.1 Epidemiology 
At the start of this research project there was limited knowledge on who was at increased risk of 
retained placenta. There was some consensus that previous retained placenta, previous abortion, 
grand multiparity (parity ≥5) and preterm delivery independently predisposed to the 
disorder4,13,41,42. However, there was only one study, dated 1991, with a sample size that 
allowed a broader risk factor analysis. In this study maternal age >30, non-Asian genetic 
descent, pre-eclampsia, delivery in a labor bed and augmented labor with oxytocin were also 
associated to retained placenta4.  
In the years 2014-2015 however, four large epidemiological studies involving retained placenta 
have been published27,29,43,44. Risk factors for retained placenta suggested by these studies are 
assisted reproductive technology, European genetic descent, stillbirth and delivery-related 
variables such as induced labor, epidural use, instrumental delivery and prolonged labor. 
Previous delivery by cesarean section has been a clear risk factor in some of these studies 
although this is contradicted by earlier studies4,27,37,44. Interestingly some of these risk factors 
were identified in case series as early as 189617. It has been speculated that some of these 
factors may predispose more to focally accretic placentas (previous uterine surgery) and some 
more to adherent placenta (preterm labor, dysfunctional labor requiring oxytocin)1. 
2.7.2 Defective placentation disorders 
Pre-eclampsia, preterm birth, fetal growth restriction (as represented by SGA birth), stillbirth and 
recurrent miscarriage are part of a group of pregnancy complications termed “defective 
placentation disorders”45. These disorders are believed to develop in substantial part as a result of 
an initial deficient placentation, with an incomplete transformation of spiral arteries into the non-
muscularized vascular system that is integral to perfusion of the placenta in normal pregnancy46. 
Perfusion will consequently be diminished or intermittent due to an exaggerated vascular 
constriction. This intermittent hypoxia results in oxidative stress in the placenta which contributes 
to a cascade of events resulting in the endothelial cell dysfunction and increased apoptosis 
characteristic of these disorders46,47. It is hypothesized that this will present clinically at different 
stages of pregnancy as early miscarriage, pre-eclampsia, preterm delivery or SGA birth depending 
on the severity of the stress46 (figure 3).  
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There are some clinical traits to these disorders that are pertinent to this research project:  
 They are epidemiologically interrelated and display similar patterns of recurrence and, 
in some cases, risk asssociations across generations48-51.  
 They display signs of increased oxidative stress or decreased antioxidiative defense 
capacity in placental tissue52.  
 They are histologically characterized by signs of decidual (maternal) placental 
underperfusion53.  
 
 
 
 
 
 
 
 
 
 
 
 
2.7.3 Oxidative stress 
Oxidative stress occurs when the cell´s antioxidative defenses are overridden by an excess 
generation of reactive oxygen species (ROS), over time resulting in cell death54. Although 
reactive oxygen species play important roles in cell signaling and immune regulation in the 
placenta, excessive oxygen is harmful to tissue55. Oxidative stress can result both from oxygen 
deficiency (hypoxia) and from alternating high and low oxygen pressure, such as occurs in pre-
eclampsia, with varying intensity in blood perfusion due to the persistent muscularity of spiral 
arteries47. Oxidative stress can be measured directly by quantifying concentrations of ROS, and 
indirectly by measuring concentrations of antioxidative enzymes or the effects of oxidative 
stress on proteins and lipids in the form of lipid peroxides or protein carbonyls54,56. In 
pregnancy and labor oxidative stress is heightened so pregnancy and peripartal disorders that 
Miscarriage
Small-for-gestational-age birth
Pre-eclampsia
Preterm birth
Stillbirth
Defective 
Placentation 
Oxidative 
Stress 
Figure 2 
Schematic figure of consequences of excessive oxidative stress with progressing 
duration of pregnancy 
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are associated to an increased degree of oxidative stress are so in relation to a state in which 
oxidative stress is already higher than usual45. 
2.7.4 Histology and relationship to placenta accreta 
Placenta accreta is a disorder in which the placenta attaches directly into the myometrium 
without intervening decidua, creating a plane of attachment that is excessively strong36. If and 
how retained placenta is related to placenta accreta is not clear. In both disorders the placenta 
does not detach spontaneously following birth of the infant. Basal plate myometrial fibers 
(BPMF) signifying increased attachment to the myometrium are increased in retained placenta 
compared to non-retained placentas57,58. Risk factors for placenta accreta such as previous 
cesarean section and previous uterine curettage may also be associated to retained placenta27,44.  
On the other hand some epidemiological and histological factors challenge this association. 
Placenta accreta is defined by an absence of the basal decidua, something which is not seen in 
the great majority of cases of retained placenta57. The increased incidence of BPMF seen in 
retained placenta does significantly correlate with hemorrhage or a prolonged third stage58,59. 
Nulliparity, previous miscarriage without surgical treatment and pre-eclampsia are risk factors 
for retained placenta but not placenta accreta60. 
2.7.5 What animal studies say 
Retained placenta in cows increases the risk of endometritis and metritis which delays milk 
yield and costs the dairy industry in the UK 16 million pounds yearly61. Studies in ruminant 
medicine are therefore numerous. Retained placenta has in these studies been associated to 
increased oxidative stress, apoptosis, inflammation, a lower ratio of prostaglandin E2 to 
prostaglandin F2alpha and an elevated steroid hormone receptor status in placental tissue61. 
Antioxidants in the form of Selenium and Vitamin E have proved to decrease the incidence of 
retained placenta62,63. Interestingly both preterm delivery and prolonged labor are risk factors 
for retained placenta in cows64. 
2.7.6 Limitations of animal studies 
In human placentation the fetal chorion is in direct contact with maternal blood (hemochorial 
placentation) whereas in ruminants discrete areas or cotyledons of the placenta attach into the 
intact maternal endometrium, creating a multicellular barrier between maternal and fetal  blood 
(epitheliochorial placentation)65. In theory hemochorial placentation would facilitate passive 
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nutrient and gaseous exchange but complicate maternal-fetal immune interactions66. What these 
differences mean to the study of retained placenta in humans however is hard to say. Perhaps of 
importance, ruminant and human placentation are both villous and the feto-maternal blood flow 
interaction is similar65. The efficiency of this gas exchange is reflected in the similar fetal-to 
placental weight ratio in these two species. This ratio indicates to what extent the placenta can 
tolerate stress before is has consequences for the viability of the fetus. A human placenta can 
compensate for a 50% tissue necrosis before severe consequences for the pregnancy ensue65. 
This compensatory capacity of the placenta is important to keep in mind when studying 
oxidative stress in relation to clinical outcome.   
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3  AIMS OF THE THESIS 
 
Study I 
 To explore the epidemiology of retained placenta in a context of contemporary obstetric 
practice and demography in particular in respect to parameters relating to dystocia and 
the use of oxytocin for labor augmentation. 
 
 To assess the severity of blood loss in retained placenta. 
 
Study II 
 To explore the epidemiological association between retained placenta and so-called 
defective placentation disorders, i.e. pre-eclampsia, spontaneous preterm birth, SGA 
birth and stillbirth. 
 
Study III 
 To assess whether gene and protein markers of oxidative stress and inflammation are 
increased in retained placentas compared to spontaneously released placentas. 
 
Study IV 
 To assess whether histological signs of maternal placental underperfusion and placental 
inflammation are increased in retained placental tissue compared to spontaneously 
released placentas. 
 
 To assess whether retained placenta shows histological signs of increased placental 
attachment. 
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4 METHODS 
 STUDY DESIGNS 
 
Study I is a case-control study of all cases of retained placenta (n=408) occurring after vaginal 
delivery at Södersjukhuset, Stockholm, between January 2007 and March 2010 and the same 
number of controls giving birth at equivalent dates. Aspects of obstetric history, the current 
pregnancy, labor and delivery were compared.  
Study II is a population based cohort study of all primiparous women in Sweden with 
singleton vaginal deliveries between January 1997 and December 2009 at 32-41 gestational 
weeks (n=386 607).  The study investigates the association between retained placenta and pre-
eclampsia, preterm birth, SGA birth and stillbirth. 
Study III is a cross-sectional pilot study with prospectively collected data of 29 retained and 
31 non-retained placentas occurring after vaginal delivery between February 2013 and 
September 2014 at Södersjukhuset, Stockholm, in full-term, singleton, normal-for-gestational-
Table 1     
Overview of study designs and methods   
     
  
Study Design Inclusion Criteria 
Number of 
Participants 
Analysis Methods 
     
Study 1 Case-Control Singleton live births with retained 
placenta and time-matched controls  
816 Logistic regression 
Study II Cohort Singleton births in primiparous 
women at 32-41 gestational weeks 
without fetal malformations or 
placental abruption 
386 607 Logistic regression 
Study III Cross-Sectional Singleton full-term live births 
without pre-eclampsia, diabetes or 
SGA birth  
60 Mann-Whitney U 
test, Student t-test, 
Spearman´s rank 
correlation, logistic 
regression 
Study IV Case-Control Singleton full-term live births 
without pre-eclampsia, diabetes or 
SGA birth 
97 Mann-Whitney U 
test, Student t-test,  
logistic regression 
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age live births without pre-eclampsia or diabetes in the mother. The study investigates 
antioxidative defense capacity and inflammation in retained and non-retained placental tissue.  
Study IV is a case-control study of 49 cases of retained placenta and 47 control placentas, 
part of which were part of Study III, and selected based on the same criteria as this study. 
The study compares histological signs of maternal underperfusion, inflammation and 
increased placental attachment in retained and non-retained placentas. 
 NOTE ON STATISTICS USED 
In all studies mean and median values were compared using Students T-test and Mann-Whitney 
U test respectively depending on whether the data was normally distributed (as assessed by 
Shapiro-Wilks test of normality). Correlations were assessed using Spearman´s rank correlation 
coefficient. Risk associations were calculated as odds ratios (OR) with 95 percent confidence 
intervals (CI) using unconditional logistic regression. The null hypothesis was rejected when p< 
0.05 or when the 95% CI did not encompass 1. 
 THE SWEDISH MATERNAL HEALTH CARE SYSTEM AND STUDY DATA 
In Study I, III and IV study participants were women with vaginal deliveries at 
Södersjukhuset, a tertiary level obstetric department in Stockholm with approximately 7500 
deliveries per year. Oxytocin is routinely administered after delivery as part of active 
management of the third stage. Postpartum bleeding is subjectively assessed unless blood loss is 
estimated to exceed 1000ml in which case the blood is quantified by weighing. In Sweden data 
from maternal health care centers are linked to the women´s hospital records. At Södersjukhuset 
specialized nurses go through all patient hospital records and accord the right diagnostic codes 
at discharge. Complications during pregnancy and delivery are since 1997 classified according 
to the 10th version of International Classification of Diseases (ICD-10). 
In Study II the cohort of study participants was assembled from the whole population of 
women delivering in Sweden, of which 99.7% deliver in hospitals67. Data came from the 
Swedish National Birth Register which includes nationwide demographic data, information on 
reproductive history and complications that occur during pregnancy, delivery, and the neonatal 
period on 98% of all live births and stillbirths in Sweden68. Data on each pregnancy and 
delivery is forwarded to the Birth Register through copies of standardized antenatal, obstetric 
and pediatric records. Individual record linkage between the Birth Register and other registries 
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are possible through each individual’s unique personal registration number, assigned to each 
Swedish resident. 
 STUDY POPULATIONS 
Study I included all cases of retained placenta occurring after vaginal delivery at 
Södersjukhuset between January 2007 and March 2010 (n=427). Stillbirths and multiple births 
were excluded (n=19). Controls (n=408) were randomly selected by computer generation from 
women giving birth during the same time period. 
In Study II a cohort was created based on all vaginal births in nulliparous women in Sweden 
between January 1997 and December 2009 (Figure 4). Births of infants with fetal 
malformations and cases of placental abruption were excluded. We thus greatly increased the 
study size (n=386 607) but narrowed the scope of our analysis in the following manner: 
 Focusing on a few interrelated exposures: pre-eclampsia, spontaneous preterm birth, 
SGA birth and stillbirth. 
 
 Subanalyzing a preterm cohort of pre-eclampsia, SGA birth and stillbirth, a group 
assumed to represent more severe forms of these disorders.  
 
 Selecting only nulliparous women and thereby excluding the effect of  previous retained 
placenta which was the strongest risk factor in our analysis in Study I.  
 
 Excluding births prior to gestational week 32 since before this women with some of our 
exposures of interest (pre-eclamptic pregnancies and SGA infants) are often delivered 
by cesarean section which would distort our analysis of association to retained placenta 
in very early preterm delivery. 
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Figure 4 
Flowchart of inclusion into the study cohort of Study II 
 
 
Study III and IV are partly based on the same study group. We included all cases of retained 
placenta occurring at Södersjukhuset between February 2013 and September 2014 that were 
accessible for collection by the researchers, meaning that they were present at the time of 
manual removal of the placenta. We excluded the disorders that were shown to be associated to 
retained placenta in Study II: pre-eclampsia, preterm birth, SGA birth and stillbirth. These 
variables were associated both to our exposure (oxidative stress and inflammation) and to our 
outcome (retained placenta) and would therefore confound our analysis52,69. We also excluded 
births from mothers with diabetes which is associated to oxidative stress and was 
overrepresented among cases of retained placenta in Study I, although not a significant risk 
Singleton deliveries 
among primiparous 
women 1997-2009
N= 550 263
N=424 384
Final study cohort
N=386 607 
Exclude gestational 
age < 32+0 weeks
N=1 945
Exclude gestational 
age ≥ 42+0
N=35 832
Exclude cesarean 
section
N=100 766
Exclude fetal 
malformations
N=18 449
Exclude placental 
abruption
N=228
Exclude cases with 
ICD diagnosis without 
surgical code or vice 
versa
N=6 436
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factor in Study II70. An equivalent number of controls were randomly selected from women 
giving birth during the same time period.  
After initial inclusion, one case of placenta accreta and one case of non-diagnosed diabetes in 
the mother were excluded from Study III giving a total study group of 29 cases of retained 
placenta and 31 non-retained placentas. This same diabetic case was excluded after inclusion 
from Study IV as well as three placentas that were accidentally discarded according to routine 
protocol at the hospital resulting in a study group of 49 cases and 47 controls. 
 VARIABLES AND ANALYSIS STUDY I   
Outcomes 
1. Retained placenta defined by the Swedish National Procedure Code MBA30 (“Manual 
removal of fetal membranes, placenta or rest thereof”). All cases also has an ICD-10 
code for retained placenta recorded (ICD-10 codes O720, O722, O730 or O731). 
2. Postpartum hemorrhage as recorded in the patient records (blood loss >500ml), severe 
postpartum hemorrhage (blood loss >1000ml), very severe postpartum hemorrhage 
(blood loss >2000ml) and the need of blood transfusion. 
Exposures 
1. Variables relating to past and current obstetric history: age, parity, body mass index 
(BMI), smoking status, previous miscarriage, induced abortions, vacuum aspiration, 
ectopic pregnancies, cesarean section or retained placenta. 
2. Variables relating to current pregnancy: hypothyroidism, pregnancy induced or 
gestational diabetes mellitus, hypertension of pregnancy, pre-eclampsia and SGA birth. 
3. Variables relating to labor and delivery in the current pregnancy: gestational age at 
delivery, prelabor rupture of membranes > 48hrs (PROM), induced labor, epidural use, 
fever during delivery (T >38ºC), augmented labor by oxytocin (use and duration), labor 
duration and instrumental delivery. 
Statistical analysis 
Associations to retained placenta were calculated using unconditional logistic regression. No a 
priori assumptions were made about associations between retained placenta and each exposure. 
Duration of labor and duration of augmented labor were stratified into quantile categories. 
Univariate logistic regression was performed first. The final multivariate model was created 
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using a forward stepwise regression model in which each exposure variable was entered in 
order or strength (combined assessment of OR and 95% CI). A sensitivity analysis to test the 
robustness of results was made using a backward stepwise model. The subanalysis of retained 
placenta and risk of postpartum hemorrhage was performed using unconditional regression 
analysis. 
 VARIABLES AND ANALYSIS STUDY II   
Outcome 
Retained placenta was defined by the combined existence in patient records of the ICD-10 code 
for retained placenta (ICD-10 codes O720, O722, O730 or O731) and the Swedish National 
Procedure Code for manual removal of the placenta, MBA30 (“Manual removal of fetal 
membranes, placenta or rest thereof”).  
Exposures 
1. Pre-eclampsia defined as blood pressure ≥ 140/90 and proteinuria > 0.3 g/24 hours; 
ICD-10 codes O14-15. 
2. SGA birth defined as birthweight 2 standard deviations or below the mean weight for 
gestational age according to the Swedish sex-specific fetal growth curve 71. Only live 
births were included. Preeclamptic pregnancies were excluded to isolate SGA birth from 
the potential causal factor of pre-eclampsia. 
3. Stillbirth, encompassing both antepartal and intrapartal death as recorded in the Birth 
Register. 
4. Spontaneous preterm birth defined by: spontaneous onset of labor (induction of labor 
excluded) of unknown cause (pre-eclampsia, SGA birth and stillbirth excluded) at 
gestational age below 37 weeks (according to ultrasound assessment at week 18-20). 
5. Preterm pre-eclampsia, SGA birth and stillbirth defined as the occurrence of these 
disorders in the sub-cohort of deliveries prior to 37 gestational weeks. 
Statistical analysis 
The association between retained placenta and each exposure was calculated in turn according 
to the models specified above, using unconditional multivariate logistic regression. The analysis 
was then repeated when the cohort was stratified into preterm (32-36 weeks) and term (37-41 
weeks) birth groups.  
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 MANUAL PLACENTAL REMOVAL AND SAMPLING STUDY III AND IV 
Outcome 
Retained placenta was defined as the identification during manual removal of an adherent plane 
between the placenta and the uterine wall. During manual removal one of two researchers was 
prepared to collect and sample placentas directly upon placental removal.  
Sample collection 
For Study III two periumbilical, two peripheral and one umbilical samples were taken at 
standardized sites (one cm from the periphery and umbilical insertion respectively) and 
immediately frozen at -70ºC. The time duration from delivery of the placenta until the samples 
were frozen was recorded. The remaining placenta was analysed histologically at the division of 
perinatal pathology as part of Study IV. Full-thickness placental biopsies were collected from 
three standardized macroscopically normal sites as well as sites with focal macroscopic 
changes. A complete 1 cm thick full-lumen sample of the umbilical cord was collected. The 
samples were fixed in buffered formalin, paraffin embedded, cut and stained for a detailed 
standardized microscopic analysis. Within a few days of a retained placenta being recruited to 
the study a spontaneously delivered placenta was randomly selected and sampled as a control. 
Variables relating to reproductive history and current delivery, and data relating to the newborn, 
were recorded for each woman admitted to the two studies.  
 VARIABLES AND ANALYSIS STUDY III 
Molecular markers 
In Study III protein and gene expression of Glutathione Peroxidase I (GPX1) and gene 
expression of NFκB (Nuclear Factor Kappa-light-chain-enhancer of activated β-cells) and its 
inhibitor IκBα (Nuclear Factor Kappa-light-chain-enhancer of activated β-cells inhibitor, alpha) 
were analysed and compared between retained and non-retained placentas. These markers of 
oxidative stress and inflammation were chosen based on the following premises: 
1. GPX1 is the main cellular isoform of the antioxidative enzyme GPX, accounts for most  
enzymatic activity in placental tissue and is vital to cellular antioxidative defense, as 
illustrated by the fatal effect of severe oxidative stress on GPX1 knock-out mice72,73. 
Several studies have shown that GPX1 enzyme activity and/or mRNA expression is 
decreased in cases of pre-eclampsia74-76.  
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2. NFκB is a transcription factor which upregulates GPX1 in response to oxidative stress, 
modifies inflammatory response in the placenta and may be upregulated in cases of pre-
eclampsia77-80. IκBα is the inhibitor of NFκB.  
Laboratory analysis 
Gene expressions of GPX1, NFκB and IκBα were analyzed by real-time quantitative reverse 
transcriptase polymerase chain reaction analysis (qrt-PCR). Total RNA was extracted from each 
placental sample using Bullet Blender Homogenizer (Next advance Inc., USA) and Aurum total 
RNA mini kit (Bio-Rad Laboratories Inc., USA). Twice the amount of recommended DNase1 
was used to ascertain no remaining cDNA. The quantity of total RNA was measured using the 
Pico Drop spectrophotometer (PicoDrop LTD, UK). Five micro litres of each RNA sample 
were analyzed using 1% Agarose gel electrophoresis in TAE buffer and visualized using 
ethidium bromide staining.   
Both cDNA synthesis and real-time PCR analysis of GPX1, NFκB and IκBα were performed 
using iTaq™ Universal SYBR® Green One-Step Kit (Bio-Rad Laboratories Inc., USA. 
Specific primers were used to measure the gene expression of GPX1, NFκB, IκBα and the 
housekeeping gene tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein 
zeta (YWHAZ). The real-time PCR products were visualized in 2% agarose gel electrophoresis 
and ethidium bromide staining. Each sample was analyzed in duplicates and the mean value of 
each sample was used for quantification. The formula of Livak and Schmittgen was used for 
quantification of samples and normalization was performed using the housekeeping gene 
YWHAZ81. 
Sandwich enzyme linked-immunosorbent assay (ELISA) was used for quantitative 
determination of intracellular GPX1 protein in placental samples using the GPX1 human 
intracellular ELISA kit (Adipogen International Inc., USA). A standard curve was performed. 
The absorbance was measured at 450 nanometers using Ascent software v. 2.6. (Thermo 
Labsystems, Finland). All samples were analysed in duplicates and the researcher was blinded 
to outcome group. 
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Statistical analysis 
Median values of gene and protein expressions of GPX1and gene expressions of NFκB and 
IκBα between retained and non-retained placentas were compared. Levels of GPX1 protein 
were categorized as low or high according to a cut-off based on an ROC curve. The rationale for 
categorization of GPX1 protein levels was that concentrations were not normally distributed. 
Associations between a low level of GPX1 protein and retained placenta were calculated using 
unconditional univariate logistic regression. 
 VARIABLES AND ANALYSIS STUDY IV  
Histological features 
1. Histological features of maternal underperfusion: artheriolopathy, placental infarcts, 
giant trophoblastic multinucleated giant cells, syncytical knots/villous agglutination, 
chorangiosis, septal cysts and fibrotic villi.  
 
2. Histological placental inflammation: acute chorionitis, chorioamnionitis, vasculitis of 
fetal vessels or funisitis. 
 
3. Macroscopic characteristics consistent with placental underperfusion: Weight in relation 
to gestational age, fetal to placental weight ratio, shape, width and thickness.  
Other placental features recorded were umbilical coiling and insertion, distal villous immaturity, 
thrombosis of the fetal stem vessels, intervillous thrombosis, chronic villitis, placental 
abruption, and signs of increased placental attachment in the form of placental accreta or basal 
plate myometrial fibers (BPMF). 
Histological analysis 
The placentas were weighed after formalin fixation and removal of the fetal membranes and the 
umbilical cord and defined < the 10th, between the 10th and 90th, or > the 90th percentile for 
gestational age according to a reference curve82. Villous maturation was evaluated in relation to 
gestational week. The size and configuration of the dominant villous component was assessed, 
including the layer of trophoblasts and the number and morphology of blood vessels. Fresh and 
older infarctions were included. Histological sections were taken from at least one of the 
macroscopically suspected infarcted areas as well as otherwise macroscopically disrupted areas. 
The proportion of infarcted placental tissue was calculated by dividing the total volume of the 
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infarcts by the total volume of the placenta. Histological variables were defined and recorded 
according to pre-specified definitions (Appendix: histological definitions). 
All histological analysis was performed at Karolinska University Hospital, Department of 
perinatal pathology by an experienced perinatal pathologist. The pathologist was blinded in 
regard to the outcome group for all microscopic analysis.  
Statistical analysis 
Mean and median values relating to size and shape were compared. Categorical variables 
relating to maternal placental underperfusion, placental inflammation, placental attachment and 
fetal vascular trombo-occlusive disease were compared using unconditional univariate logistic 
regression. 
 ETHICAL CONSIDERATIONS 
Study I 
 All patient data was anonymized and coded. The code for each participant can only be 
traced back to the participants´ identity through a secure server accessible to only two of 
the researchers in the study. 
Study II 
 The data for the patient cohort in study was retrieved from the Swedish Medical Birth 
Register. The researchers only had access to anonymized data. All data analysis was 
performed at the physical location of the Unit of Clinical Epidemiology at Karolinska 
Institutet which means that no patient data ever left the secure server of those premises.  
Study III and IV 
 Written informed consent was obtained from all study participants. The participants 
were informed of the purpose of the study and of the fact that she could at any time 
demand that the biological material applicable to her be destroyed. The sample 
collection was performed after delivery and therefore involved no physical discomfort to 
the participant. Placental samples were stored in an approved biobank. The sampled 
material was marked in code which can only be traced back to the participants´ identity 
through a secure server accessible to only one of the researchers in the study. No further 
studies can be performed on this material without further approval by the ethical board.  
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Ethical permits have been obtained for all four studies from the Local Ethics Committee at 
Karolinska Institutet, Stockholm, Sweden (2010/438-31/4, 2012/1250-31/4, 2012/15-31/2).  
5 RESULTS 
 STUDY I: RETAINED PLACENTA IN MODERN OBSTETRICS 
5.1.1 Summary of main findings 
Nulliparity, previous placental retention, a history of recurrent miscarriage or abortion, pre-
eclampsia, preterm birth and augmented labor independently increased the risk of retained 
placenta in our study, whereas smoking at the start of pregnancy lowered the risk. In regard to 
augmented labor there was a dose-response relationship between duration of oxytocin exposure 
and risk of retained placenta. Retained placenta was significantly associated to postpartum 
hemorrhage, severe and very severe postpartum hemorrhage as well as the need for blood 
transfusion (Table 2).  
5.1.2 Related findings  
There were 427 cases of retained placenta among 16 209 vaginal deliveries at Södersjukhuset 
between January 2007 and March 2010, giving an incidence of retained placenta of 2.6 %.  
There was no difference in median age, BMI or gravidity between cases and controls. There 
was no difference in median gestational age, but preterm and postterm deliveries were more 
common among retained placentas. In the univariate model women with retained placenta were 
more likely to have had a previous vacuum aspiration. In the current pregnancy they were more 
likely to have had prelabor rupture of membranes (PROM), induced labor, received epidural 
anesthesia, developed fever during delivery and given birth by instrumental delivery. 
Hypothyroidism and diabetes were numerically more common among women with retained 
placenta. None of these variables were associated to retained placenta in the multivariate model. 
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Table 2        
Main risk factors for retained placenta and association between retained placenta and 
postpartum hemorrhage in Study I 
       
  Rate and Risk of Retained Placenta 
 Cases= 408 Controls= 408 
 
Adjusted 
Odds Ratio 
 
Confidence  
  n % n % Interval (95%) 
Model 1a       
History, pregnancy and delivery       
Previous Retained Placentab 22 (5.4%) 3 (0.7%) 12.61 (3.61-44.08) 
Previous Miscarriages       
1 previous miscarriage  93 (23.0%) 75 (18.4%) 1.52 (1.04-2.21) 
≥2 previous miscarriages  29 (7.2%) 16 ( 3.9%) 2.62 (1.31-5.20) 
≥1 previous abortionb 98 (24.2%) 74 (18.2%) 1.58 (1.09-2.28) 
Parity       
1 para  137 (33.6%) 158 (38.7%) 0.78 (0.55-1.11) 
≥2 para 35 (8.6%) 67 (16.4%) 0.40 (0.24-0.70) 
Smoking at start of pregnancy 5 (1.4%) 15 (4.3%) 0.28 (0.09-0.88) 
Pre-eclampsia 27 (6.6%) 8 (2.0%) 2.85 (1.20-6.78) 
Augmented labor by oxytocin 228 (55.9%) 160 (39.2%) 1.74 (1.21-2.48) 
Duration of augmented labor        
<50th percentile (10-194 min) 92 (22.5%) 100 (24.5%) 1.24 (0.83-1.84) 
50-75th percentile (195-415 min)  59 (14.5%) 43 (10.5%) 2.00 (1.20-3.34) 
 >75th percentile (>415min)  77 (18.9%) 17 (4.2%) 6.55 (3.42-12.54) 
Preterm delivery 32 (7.8%) 12 (3%) 3.28 (1.60-6.70) 
Model 2c       
Postpartum period             
Blood loss≥500 ml 383 (93.9%) 126 (69.1%) 33.07 (20.57-53.16) 
Blood loss≥1000ml 305 (74.8%) 27 (6.6%) 43.44 (26.57-71.02) 
Blood loss≥2000ml 157 (38.5%) 3 (0.7%) 111.24 (27.26-454.00) 
Blood transfusion 126 (30.9%) 5 (1.2%) 37.48 (13.63-103.03) 
a Model 1 adjusted for previous retained placenta, previous miscarriage, previous abortion, pre-eclampsia and   
duration of augmented labor. 
b There were 4 cases with missing values for data on miscarriage, 3 on previous abortion. 
c Model 2 was adjusted for labor duration ≥12 hrs. 
 
5.1.3 Augmented labor and labor duration 
Augmented labor by oxytocin was an independent risk factor for retained placenta and the risk 
of retained placenta increased in an exponential fashion with increasing duration of use (Figure 
5). Both women with and without retained placenta had a median latency phase of 5 hours (p= 
0.74). In the univariate analysis, women with retained placenta were more likely to have labor 
duration of more than 12 hours. Both the median duration of the active phase of the first stage 
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of labor (p<0.04) and the second stage of labor (p<0.001) were longer in cases of retained 
placenta compared to controls. Neither duration of labor over 12 hours nor increasing duration 
of the second stage (categorized by quantiles of time) were however associated to retained 
placenta in the multivariate model (Figure 5). 
Figure 5 
Risk of retained placenta (odds ratio) in each quantile of duration of augmented labor 
 and duration of the second stage of labor  
 
 
5.1.4 Postpartum hemorrhage 
Median blood loss was 1600ml among women with retained placenta and 400ml among 
controls (p>0.001). Retained placenta increased the risk of all measures of postpartum 
hemorrhage, particularly of severe (>1000 ml) and very severe (>2000 ml) hemorrhage. There 
was a weak but significant negative correlation (r= -0.2, p<0.001) between total blood loss and 
time from birth of the infant till manual removal of the placenta among cases of retained 
placenta.  
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 STUDY II: RETAINED PLACENTA AND DEFECTIVE PLACENTATION  
5.2.1 Main findings 
Defective placentation disorders, i.e. pre-eclampsia, spontaneous preterm birth, SGA birth and 
stillbirth, were all associated to an increased risk of retained placenta. The association was 
stronger for preterm pre-eclampsia and preterm SGA birth. There was a dose-response 
relationship in respect to spontaneous preterm birth, with increasing risk of retained placenta for 
decreasing gestational age at delivery (Table 3 and 4).  
 
 
Table 3     
Risk of retained placenta associated to disorders of defective placentation 
     
  Rate and Risk of Retained Placenta 
  
Number  % 
Odds Ratio (95% Confidence Interval) 
Crude Adjusted a 
Preeclampsiab      
No 7 982 2.13 Ref Ref 
Yes 426 3.55 1.69 (1.53-1.87) 1.37 (1.21-1.54) 
Stillbirthb     
No 8 340 2.16 Ref Ref 
Yes 68 5.80 2.79 (2.18-3.56) 1.71 (1.28-2.29) 
Small for gestational 
age birth c     
No 7 456 2.08 Ref Ref 
Yes 247 3.01 1.46 (1.28-1.66) 1.47 (1.28-1.70) 
Spontaneous preterm 
birthd     
No 6 467 1.97 Ref Ref 
35-36 weeks 336 2.90 1.49 (1.33-1.66) 1.55 (1.37-1.75) 
32-34 weeks 182 4.60 2.41 (2.07-2.80) 2.35 (1.97-2.81) 
          
a All models were adjusted for maternal age, body mass index, country of birth, previous miscarriages, year 
of delivery, gestational age, epidural analgesia, labor dystocia, instrumental vaginal delivery, and large for 
gestational age birth weight. Preeclampsia was additionally adjusted for premature rupture of membranes and 
induction of labor. Stillbirth was additionally adjusted for induction of labor. Small-for-gestational-age birth 
was additionally adjusted for induction of labor. Spontaneous preterm labor was additionally adjusted for  
prelabor rupture of membranes. 
b In analyses of preeclampsia and stillbirth, total number of births were 386 607.  
c Analysis only includes live births. Pregnancies with preeclampsia were excluded. 1 164 pregnancies with 
missing data on birth weight were not included in the analysis. Total number of births analyzed was 373 466. 
d Analysis only includes live births. Pregnancies with pre-eclampsia, SGA birth or induction of labor were 
excluded. Total number of births analyzed was 344 307. 
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5.2.2 Related Findings 
The overall rate of retained placenta was 2.17%. Compared to women with spontaneous 
placental expulsion, those with retained placenta were on average older and had a somewhat 
higher BMI. In the univariate analysis they were more likely to have been born in a Nordic 
country, have had previous miscarriage, have used assisted reproductive technology, deliver 
preterm, have PROM, induced labor, epidural analgesia, labor dystocia, give birth by 
instrumental delivery and give birth to a large-for-gestational-age (LGA) infant. 
In the adjusted analysis only maternal age and previous miscarriage remained as strong 
independent risk factor for retained placenta. Both these variables showed a dose-response 
relationship to retained placenta with increasing risk according to increasing age and number of 
miscarriages respectively. In the analysis of births occurring at term, LGA birth was also an 
independent risk factor for retained placenta. The remaining variables listed above and adjusted 
for in the analysis were only marginally associated to retained placenta (adjusted ORs ≤1.30.).  
 
Table 4  
Defective placentation disorders and risk of retained placenta in term and preterm deliveries 
 
  Retained Placenta 
                                   Preterm delivery  Term delivery 
  
n % Adjusted a 
 OR (95% CI) 
n % Adjusted b 
 OR (95% CI) 
Pre-eclampsia        
No 1 064 3.53 Ref 10509 2.06 Ref 
Yes 54 4.83 1.69 (1.25-2.28) 372 3.42 1.32 (1.16-1.50) 
Small-for-gestational- 
age birthc        
No 366 3.46 Ref 7605 2.02 Ref 
Yes 25 6.39 2.19 (1.42-3.38) 222 3.11 1.43 (1.23-1.66) 
Stillbirth       
No 351 3.59 Ref 753 2.09 Ref 
Yes 15 4.10 1.10 (0.63-1.92) 53 6.58 2.36 (1.71-3.27) 
n=number, OR= odds ratio; CI, confidence interval.      
a Adjusted for maternal age, country of birth, previous miscarriages, year of delivery, gestational age, PROM and 
instrumental vaginal delivery. In analyses of pre-eclampsia and stillbirth, total number of births were 18 756.  In 
analysis of SGA birth, total number of births was 17 291. 
b Adjusted for maternal age, body mass index, country of birth, previous miscarriages, year of delivery, gestational 
age, induction of labor, epidural analgesia, labor dystocia, instrumental vaginal delivery, and large-for-gestational-
age birth. In analyses of pre-eclampsia and stillbirth, total number of births were 367 851. In analysis of small for 
gestational age, total number of births was 356 175.  
c Defined as a live born infant with a birth weight of >2 standard deviations below the mean birth weight for 
gestational age according to the sex specific Swedish fetal growth curve. Pregnancies with pre-eclampsia and 
those missing data on birth weight were excluded. 
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 STUDY III: RETAINED PLACENTA, OXIDATIVE STRESS, INFLAMMATION 
5.3.1 Main findings 
Women with retained placenta were more likely to have a low level of GPX1 protein 
concentration in placental tissue compared to women without retained placenta and this 
association was strengthened when the analysis was adjusted for duration of labor 
augmentation. Retained placental tissue showed a tendency of lower median GPX1 protein 
concentrations compared to non-retained placentas but the differences were not statistically 
significant (Table 5 and 6).  
Table 5       
Median protein concentration or gene expression of GPX 1, NFκB and IκBα 
in retained and non-retained placenta 
 
  Retained Placenta Non-Retained Placenta   
  
Median Interquartile 
Range 
Median Interquartile 
Range 
Difference 
(p-value) 
GPX 1 
concentration 
ng/ml 
     
periumbilical 13.32 (9.81) 17.96 (12.95) p= 0.22 
peripheral 13.27 (16.72) 19.09 (8.85) p= 0.07 
GPX 1 mRNA 
expressiona 
     
periumbilical 1.13 (1.13) 0.88 (0.88) p= 0.08 
peripheral 1.32 (0.91) 1.18 (1.12) p=0.47 
IκBα mRNA 
expressiona 
     
periumbilical 1.14 (1.92) 0.95 (0.95) p= 0.16 
peripheral 1.96 (4.86) 0.99 (2.36) p= 0.25 
NFκB mRNA 
expressiona 
     
periumbilical 1.02 (0.45) 0.99 (0.42) p= 0.71 
peripheral 1.22 (0.61) 1.04 (0.42) p= 0.17 
            
a Relative expression to YWHAZ housekeeping gene 
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Table 6     
Level of GPX 1 protein concentration and risk of retained placenta 
  
  Risk of retained placenta  
  
Unadjusted 
Odds Ratio 
 p-value Adjusted 
Odds Ratiob 
p-value 
Low valuea periumbilical GPX 1 3.82 0.02 3.54 0.08 
Low valuea peripheral GPX 1 3.95  0.02 7.00 0.01 
          
a Low-value assessment based on sensitivity-specificity analysis of ROC curve. Periumbilical GPX1  
cut-off= 15.62 ng/ml, peripheral GPX 1=19.90 ng/ml. 
b Adjusted for duration in minutes of augmented labor. 
5.3.2 Related Findings 
There were no significant differences between women with and without retained placenta in 
regard to age, parity, history of previous miscarriage, abortion or cesarean section, use of 
assisted reproductive therapy, gestational age, epidural use, induction of labor, labor duration 
over 12hours or instrumental delivery. Median duration of labor augmentation was 
significantly longer in deliveries with retained placenta. Median blood loss in cases of 
retained placenta was 1600 ml compared to 400 ml in the group without retained placenta (p 
< 0.001). There was no significant difference in fetal birthweight or placental weight between 
deliveries with and without retained placenta.  
GPX1, NFκB and IκBα mRNA were detected at all placental sampling sites. Median 
periumbilical and peripheral GPX1 gene expressions were numerically higher in retained 
placentas (1.13 vs 0.88 for periumbilical samples and 1.32 vs 1.18 for peripheral samples) 
which approached statistical significance for periumbilical sample (p=0.08) but was statistically 
non-significant in peripheral samples (p=0.47). There was no significant difference in median 
periumbilical or peripheral NFκB and IκBα gene expressions between retained and non-retained 
placentas.  
Periumbilical and peripheral GPX1 protein concentrations did not significantly correlate with 
duration of labor, duration of augmented labor or total blood loss. Median duration from birth of 
the infant until placental delivery was 1h 22 min for retained placentas and 8min 13sec for 
spontaneously released placentas (p < 0.001). Duration until placental delivery did however not 
correlate with peripheral or periumbilical GPX1 protein concentrations in either group. 
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 STUDY IV RETAINED PLACENTA AND PLACENTAL UNDERPERFUSION 
5.4.1 Main findings 
All histological markers of placental maternal underperfusion were numerically more common 
in retained placentas with the exception of chorangiosis. Overall, signs of maternal 
underperfusion were significantly more common among retained placentas compared to 
spontaneously released placentas and when small placental size for gestational age was included 
as a marker of placental insufficiency, this difference was more marked. Retained placentas had 
a relatively smaller surface area and were more likely to have an oblong shape. Accessory lobes 
and placentas below the 10th centile for gestational age were numerically more common among 
retained placentas although the difference was not statistically significant. 
5.4.2 Related findings 
There were no significant differences between women with and without retained placenta in 
regard to age, parity, history of previous miscarriage, abortion or cesarean section, use of 
assisted reproductive therapy, gestational age, epidural use, induction of labor, labor duration ≥ 
12 hours or instrumental delivery. Women with retained and without retained placenta received 
augmented labor at similar rates, however the median duration of augmented labor was 
significantly longer for those who went on to develop retained placenta (p=0.01). 
The differences in mean placental weight and median fetal to placental weight ratio between 
retained and non-retained placentas were not statistically significant. Signs of fetal vascular 
thrombo-occlusive disease in the form of intervillous thrombosis, thrombosis of fetal vessels, 
chorionic villous immaturity, and chronic villitis were similar between retained and non-
retained placentas. There was no statistically significant difference in individual or combined 
markers of acute placental inflammation. 
Focal placenta accreta was numerically, but statistically not significantly, more common in 
retained placentas compared to non-retained placentas (12.3% vs 4.3%; 95% CI 0.60-16.40). 
BPMF were however significantly more prevalent in retained compared to non-retained 
placentas (22.4% vs 3.4%; 95% CI 1.36-31.22). Median blood loss in cases of retained placenta 
with and without focal placenta accreta, and with and without BPMF, was not significantly 
different and was consistent with the median blood loss for retained placenta overall (1500 ml).  
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Table 7 
Macroscopic and histological features of placental underperfusion in retained and non-retained 
placentas 
  Non-retained placenta 
(n=47) 
Retained placenta (N=49) Association 
to retained 
placenta  
Significance  
 
 
p-value or 
95% CI   Number % Number % Odds Ratio 
Macroscopic 
Features 
      
Placental surface 
area median cm2 
(IQR) 
396 341-418 342 288-432  p=0.05 
Oblong shapea  3 6.4% 11 26.2% 5.24 1.34-20.21 
Placental weight for 
gestational ageb 
      
<10th percentile 12 25.5% 21 42.9% 2.02  (0.84-4.88) 
>90th percentile 5 10.6% 2 4.1% 0.46 (0.08-2.58) 
Accessory lobes 1 2.1% 7 14.3% 7.67 (0.91-64.94) 
Histological Features       
Artheriolopathy 0 0% 1 2.0% nc nc 
Villous infarction 9 19.1% 9 18.4% 0.95 (0.34-2.65) 
Infarcted volume       
1-5% 1 2.1% 3 6.1% 3.14 (0.31-31.30) 
>5% 0 0% 2 4.1%   
Grouped 
trophoblastic 
multinucleated giant 
cells 
7 14.9% 11 22.4% 1.65 (0.58-4.71) 
Villous syncytial 
knots 
1 2.1% 6 10.2% 5.27 (0.59-46.54) 
Villous agglutination 1 2.1% 4 8.2% 4.09 (0.44-38.01) 
Chorangiosis 2 4.3% 1 2.0% 0.47 (0.04-5.35) 
Placental septal cysts 3 6.4% 5 10.2% 1.67 (0.38-7.40) 
Fibrotic villi 0 0% 2 4.0% nc nc 
Any sign of placental 
underperfusionc 
13 27.7% 24 49.0% 2.51 1.07-5.87 
Any sign of placental 
underperfusion 
including placental 
weightd 
20 42.6% 36 73.5% 3.74 1.59-8.82 
IQR=interquartile range, n=number, nc=not computable. CI =confidence interval, in parenthesis=non-significant. 
a Defined as a ratio of larger width to lesser width ≥ 1.3. 
b According to a reference curve of placental weight for gestational age 82. 
c Presence of one or more of following characteristics: artheriolopathy, infarcted placental volume >1%, grouped  
trophoblastic multinucleated giant  cells, villous syncytial knots or agglutination, chorangiosis, fibrotic villi,   
placental septal cysts. 
d Including also placentas <10th percentile for gestational age. 
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6 METHODOLOGICAL CONSIDERATIONS 
 SYSTEMATIC ERROR 
Systematic error in a study arises because of incorrect selection of study groups, incorrect 
classification of the variables under study or lack of adjustment for factors that interact with 
these variables to the extent that they affect results.  
6.1.1 Selection bias 
All studies were designed with attention to the risk of selection bias, the selection of either cases 
or controls that differ in their exposure-to-outcome distribution from the population from which 
the study group is recruited. Study I thus included all consecutive cases of retained placenta 
during a three year period and controls were chosen randomly from the same population. As a 
national register-based study, Study II included the whole relevant exposed and unexposed 
populations. Arguably however, a certain selection bias is introduced by the necessary exclusion 
of deliveries by cesarean section in both these studies. The question is if pregnancies delivered 
by cesarean section are different from pregnancies with vaginal deliveries in a way that would 
affect the associations studied.  
Cesarean section is more likely to be performed in a pregnancy with a history of previous 
cesarean section or pregnancies complicated by pre-eclampsia, SGA birth or prolonged labor. If 
these factors are associated to retained placenta the relative risks for exposed and unexposed 
participants in the study would remain unaffected as long as the exposed excluded were not 
more likely to develop retained placenta than the exposed included. A woman with a history of 
cesarean section would be more likely to be delivered by cesarean section also in her next 
pregnancy and thus be excluded from Study I. Her risk of retained placenta may also be 
increased compared to a woman without previous cesarean section, but her relative risk 
compared to a woman with previous cesarean section who was included in the study would 
probably not be different27,44. However, pregnancies with severe pre-eclampsia and fetal growth 
restriction may be at increased risk both of exclusion from the study because of delivery by 
cesarean section, and retained placenta compared to pre-eclamptic and SGA births that were 
included in the study. If this is the case the strength of the associations found between pre-
eclampsia, SGA birth and retained placenta in Study II may be underestimated, a so-called type 
II error. A similar “loss to follow-up” bias may occur in the analysis of prolonged or augmented 
labor and retained placenta in Study I. Increasing duration of labor would be associated both 
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with exclusion (delivery by cesarean section) and, if our results are correct, an increasing risk of 
retained placenta.  
Study III and IV recruited participants from the same study population as Study I. For 
logistical reasons not all consecutive cases were included, but there is no reason to believe that 
the ones included, which were primarily from daytime deliveries, differed in their exposures 
from the ones that were not included. Controls were randomly chosen. No women asked to 
participate declined to do so.  
6.1.2 Information bias and confounding 
6.1.2.1 Study I and II 
In both Study I and II outcome and exposures were clearly defined. In the study setting 
relevant to Study I, all medical records are routinely examined by specialist nurses after 
discharge to assure a correct diagnostic record. In addition to this, augmented labor and labor 
duration in each participant was assessed by the researcher in individual patient records and 
partograms. The rates of the variables studied are therefore likely to be reliable for both cases 
and controls, minimizing information bias. In Study II each epidemiological model was built so 
as to make the relevant exposure as specific as possible. The registration in the Birth Register of 
gestational age at delivery, birthweight and stillbirth, exposures relevant to Study II, are 
considered highly reliable. The record of the ICD-9 diagnosis for pre-eclampsia in the Register 
has been validated83. However some variables in the Register are incompletely recorded. The 
incidence of oxytocin use was 8 % among the nulliparous women in Study II as compared to 
63% among nullipara in Study I, which more closely approximates empirical clinical practice. 
Although associated to retained placenta, oxytocin is not known to be associated to any of the 
study exposures and its incomplete inclusion in the model should therefore not affect the main 
associations studied. 
During the years 1997-2001, 1.4% of births were diagnosed with the outcome retained placenta 
in the Register, whereas the corresponding rate during 2006-2009 was 2.7%. The rate increase 
most likely reflects better registration of the diagnosis during the later years and we adjusted for 
year of delivery in our statistical models. It is probable that retained placenta was better 
recorded in Study I. However, the studies were in consensus in regard to the associations found. 
The fact that outcome may be to some extent non-differentially misclassified in Study II would 
tend to push results towards the null (type II error). Error would therefore be on the cautionary 
side. Consistent with this associations were somewhat weaker in Study II.  
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6.1.2.2 Study III  
In Study III and IV the outcome retained placenta was specifically defined and verified as an 
adherence to the uterine wall. Strict inclusion criteria limited confounding that would otherwise 
have been difficult to adjust for in studies of this size. Pre-eclampsia, diabetes, preterm birth, 
SGA birth and stillbirth, factors that are associated both with retained placenta and the 
molecular and histological presentation of oxidative stress and/or inflammation, were 
excluded52,69. Other confounding factors that could hypothetically increase oxidative stress 
levels in placental tissue, and could not be excluded, such as prolonged labor and postpartum 
hemorrhage did not correlate with GPX1 levels in Study III. Duration of labor was not 
significantly different amongst retained and non-retained placentas. Duration of augmented 
labor was however significantly longer in cases of retained placenta.  For this reason duration of 
oxytocin exposure was adjusted for in the regression analysis. It is still possible however that 
augmented labor, prolonged labor and hemorrhage represent residual confounding in the 
analysis of GPX1 gene and protein levels across groups.  
Placental samples from both groups in Study III were frozen within approximately 5 minutes 
of sampling, reducing potential oxidative damage to the placental tissue from exposure to air. 
All laboratory assessments were done in duplicates. The researcher performing the laboratory 
analysis was blinded to outcome group.  
There is however a black box to gene and protein research on retained placenta inherent to the 
diagnosis itself. By definition retained placentas have been attached to the uterine wall for at 
least 30 minutes before samples are taken. Although the time from placental detachment till 
samples are frozen can be kept short and equal between cases and controls, it is difficult to 
adjust for this period of attachment or to know in which direction oxidative stress levels go 
during this phase.  In an attempt to answer this question we analyzed GPX1 gene and protein 
expression in placental samples collected at different time intervals after placental delivery in 
six placentas exposed to air. The results showed that although both gene and protein levels 
remained fairly stable up until 30 minutes after placental delivery, there was a small but 
significant increase in GPX1 protein expression84 (Figure 6). This increase possibly signifies a 
compensatory increase of antioxidative enzymes in the placenta after the stress of labor has 
ceased. It is uncertain however if these results can be extrapolated to retained placentas where 
blood flow from the fetus is cut-off but where a plane of attachment to the uterine wall remains.  
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Systematic error is also an assessment of to what degree the study measures what it claims to 
do. GPX1 and NFκB are adequate overall markers of oxidative stress, inflammation and the 
overlap between these two processes. As a pilot study, Study III was however small in the 
scope of its analysis which consequently limits to what extent the study can describe the role of 
oxidative stress and inflammation in retained placenta. To reliably assess oxidative stress would 
require an analysis of all subtypes of GPX, other antioxidative enzymes as well as by-products 
of oxidative stress in placental tissue. In a more specific assessment of the association between 
retained placenta and pre-eclampsia, the analysis of predictive markers of impaired 
angiogenesis such as serum or placental VEGF (vascular endothelial growth factor) and sFLT-1 
(soluble fms-like tyrosine kinase-1) in retained placenta could be considered. These latter 
factors are also active in inflammatory pathways and could tie into a further analysis of the role 
of inflammation in retained placenta. An analysis of inflammation might also include products 
of activated inflammatory pathways in the placenta such as tissue tumor necrosis factor-alpha, 
placental interleukins, cyclooxygenase-2, and markers of apoptosis. 
Figure 6 
Change in median periumbilical and peripheral GPX1 protein concentrations in placental tissue 
exposed to air over time. 
 
*p <0.05 
6.1.2.3 Study IV 
Outcome was strictly defined in Study IV and disorders with histological characteristics that 
would confound the analysis were excluded. The researcher performing the microscopic 
analysis was blinded to outcome group. The delivery-related factors discussed above may be 
relevant to Study III in that genes and proteins involved in the regulation of oxidative stress 
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and inflammation can alter their expression in the time span of labor and delivery. Histological 
features related to oxidative stress and inflammation will however take longer to develop and do 
not need to be accounted for in the analysis. 
 RANDOM ERROR 
Random error refers to the unpredictable variability in measurements due to chance that decide 
with what degree of statistical confidence results can be stated.  
6.2.1 Precision 
Study I represents a smaller epidemiological study. The fact that medical records were 
individually assessed limited the size of the study group which prevented the study rare of rare 
exposures such as SGA birth. The study was however well-powered to the detailed study of 
common exposures such as duration of labor and augmented labor, factors that could also be 
validated by the researcher in individual medical records. In contrast Study II greatly increased 
the sample size at the cost of somewhat lower specificity in recorded variables. The study size 
enabled the study of associations between retained placenta and several interrelated rare 
exposures.  
Molecular and histological analysis is resource intensive which often limits study group size.  
Both Study III and IV would have benefited from a larger study group. Sample size was 
decided in a power calculation which included an estimate of variance in GPX1 concentrations 
and baseline incidences of histological features respectively. Placental sampling in both Study 
III and IV was performed at standardized locations and layers. Molecular and histological 
analysis was performed according to standard protocols. Intersample variability in placental 
tissue in Study III was however larger than expected. In Study IV the incidence of histological 
pathology was more common than expected in the control placentas from full-term healthy 
pregnancies. This variability limited to what extent both studies could distinguish differences 
with a high degree of confidence. 
6.2.2 Variability in levels of oxidative stress 
The placenta is a setting of concentrated oxygen metabolism making the study of oxidative 
stress in pregnancy and labor essentially complex55. Oxidative stress levels differ across the 
placenta depending on proximity to the umbilical insertion and layer of the placental 
tissue56,74,85,86. Prolonged labor induces oxidative stress and apoptosis in the placenta and 
activates inflammatory pathways and angiogenic regulators56,84. Placental sampling after labor 
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may therefore increase intersample variability which would decrease the precision of the results. 
Above all, measurements may not reflect the placenta´s normal physiology, something which 
has given rise to caution against studying placental molecular biology after labor altogether56. In 
the case of retained placenta studying placentas after labor is however the only option available.  
 EXTERNAL VALIDITY 
External validity is a measure of the extent to which the results of a particular study group can 
be extrapolated to a larger national, regional or global population.  
Study I represents the obstetric context of one large urban hospital. Demographic and delivery-
related interventions vary to some extent, primarily on a rural to urban axis in Sweden, but the 
results are probably applicable to the Swedish population as a whole87. Study II was a 
population-based study meaning that sampling bias, that could otherwise limit generalizability 
on a national level, was largely eliminated. Both these study populations are however Swedish 
and the delivery-related variables studied reflect a Swedish obstetric context. The associations 
found may therefore only be applicable to a genetically similar population in a similar obstetric 
environment.  
The extent to which the findings in Study III and IV can be generalized to a larger population 
with clinical retained placenta is limited. This is because of the deliberate narrow inclusion of 
placentas only from full-term otherwise healthy pregnancies. As initial studies testing new 
hypotheses these studies aimed not so much at generalizability but at creating a platform for 
future research.   
7 DISCUSSION 
 THE RESULTS IN CONTEXT 
7.1.1 Augmented labor 
Study I found a dose-response association between labor augmentation with oxytocin and 
retained placenta which has not been shown before. Duration of augmented labor was analyzed 
instead of total dose of oxytocin administered. Given that oxytocin doses needed for optimal 
myometrial contraction are highly variable among individuals, duration of use may reflect 
oxytocin receptor saturation as well as does cumulative dose88. The study distinguished between 
augmented labor and prolonged labor and found only augmented labor to be independently 
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associated to retained placenta. A recent study found prolonged labor to be a risk factor for 
retained placenta but did not adjust for labor augmentation29. However, prolonged labor was 
suggested as a risk factor for retained placenta in studies prior to the discovery of oxytocin in 
(1953, Vincent du Vigneaud)18,28. Augmented labor and prolonged labor both reflect 
dysfunctional uterine contractility, it is therefore not unlikely that also prolonged labor is related 
to the development of retained placenta.  
The question remains how oxytocin and prolonged labor are instrumental in the development of 
retained placenta. Randomized trials have shown that although oxytocin administration after 
delivery reduces postpartum hemorrhage it does not reduce the incidence of manual removal of 
the placenta or the length of the third stage2,89. There are indications that augmented labor 
increases postpartum hemorrhage and that prolonged oxytocin exposure during labor gradually 
desensitizes myometrial cells to its effect90 91. The idea that oxytocin itself could cause 
oxidative stress is counterintuitive, most studies on its physiology indicate that it attenuates 
oxidative stress and decreases inflammation92. Possibly however, both prolonged labor and 
augmented labor render the uterus less capable of a contractile mechanism needed to detach the 
placenta postpartum. Oxytocin which is titered up as far as the frequency of contractions allow, 
would be more likely to saturate contractile capacity, predisposing both to postpartum 
hemorrhage and retained placenta.  
7.1.2 Hemorrhage 
In Study I, III, and IV the estimated median blood loss for cases of retained placenta was 
consistently between 1500 and 1600 ml. This means that the majority of women with retained 
placenta suffer severe postpartum hemorrhage. The magnitude of this risk is probably valid 
despite the fact that blood loss was to some extent subjectively assessed in these studies. 
Although it is conceivable that blood loss was selectively overdiagnosed in cases of retained 
placenta, most studies on the contrary indicate that visual assessment underestimates blood loss 
and increasingly so for larger volumes of blood lost93,94.  
An initial aim of Study I was to investigate whether increasing duration till manual removal of 
the placenta increased total blood loss. What was found was the inverse relationship, suggesting 
that expedient manual removal increases hemorrhage. Most probably this is a case of 
confounding by indication: women who bled profusely were taken to surgery without delay. 
The duration from delivery of the infant till manual removal was then in fact measuring the 
degree of hemorrhage and not vice versa. One study found gradually rising rates of hemorrhage 
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and blood transfusion in third stages of labor ≥ 30 minutes with maximum rates at 75 minutes 
postpartum. However, at 30 minutes 72% of retained placentas had already been manually 
removed - most likely those that bled profusely4. In a working clinical setting the question of 
optimal timing till manual removal seems difficult to answer and must therefore continue to be 
guided by individual clinical assessment. 
7.1.3 Defective placentation disorders 
The hypothesis of defective placentation and increased oxidative stress in retained placenta was 
derived from the results of Study I where recurrent miscarriage, pre-eclampsia and preterm 
birth were among the strongest associated risk factors, all disorders of placental origin. 
Recurrent miscarriage is, in this association, likely to represents a tendency of pregnancy loss 
and not vacuum aspiration sometimes used to treat incomplete miscarriage. Approximately 90% 
of early miscarriages reach completion with expectant management, the first line of treatment 
for incomplete miscarriage in Sweden is pharmacological and the study found no association to 
vacuum aspiration95. Study II showed that all defective placentation disorders studied were 
related to retained placenta. This was the first study to show an association between SGA birth 
and retained placenta as well as stillbirth and retained placenta. The increased risk of retained 
placenta in preterm pre-eclampsia and preterm SGA birth was also not previously known. 
Compared with pre-eclampsia and SGA birth at term, early-onset forms are usually clinically 
more severe, show an increased degree of histological and molecular-level oxidative stress and 
high resistance uterine artery flow42,96-101. The stronger risk associated with preterm disorders 
therefore supports the hypothesis of a pathophysiological association between retained placenta 
and defective placentation disorders. The increased risk of retained placenta in preterm birth has 
been shown in numerous studies but we created a model specific for spontaneous preterm birth 
that suggested that this association is not a proxy for increased rate of induction of labor or 
underlying causes of preterm birth such as pre-eclampsia, fetal growth restriction or infection. 
The dose-response association of increasing risk of retained placenta with decreasing 
gestational age at birth supports a causal relationship between spontaneous preterm birth and 
retained placenta102. 
Study I and II thus independently indicate pre-eclampsia, preterm delivery and recurrent 
miscarriage as risk factors for retained placenta. In light of what other studies have shown this 
strongly suggests that these disorders are associated to retained placenta. Since Study II was 
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performed two other studies have also corroborated an association between retained placenta 
and stillbirth29,103.  
7.1.4 Epidemiological patterns in retained placenta 
In Study II maternal age had a dose-response relationship with retained placenta with 
increasing risk of retained placenta with increasing age. Maternal age >30 or >35 has also been 
a risk factor in several previous studies on retained placenta which supports this 
association27,29,42. Maternal age is a risk factor for the development of most defective 
placentation disorders and probably reflects poorer placental perfusion with age104.  
Nulliparity was associated to retained placenta in Study I and is consistently a risk factor in 
other studies of retained placenta. Studies that represent a population with increased parity also 
suggest grand multiparity as a risk factor for retained placenta41,42. The U-formed risk curve in 
relation to parity, with increased risk for the nullipara as well as the grand multipara, reflects 
that which has been suggested in the association of pre-eclampsia to parity105,106.  
Like pre-eclampsia, the strongest risk factor for retained placenta is having had the diagnosis in 
a previous pregnancy107. One study found that increased inter-pregnancy interval increased the 
risk of retained placenta, as it increases the risk of pre-eclampsia44. A recent analysis of the 
genetic component in postpartum hemorrhage found that most family clustering occurred for 
hemorrhage due to retained placenta108. Here again, retained placenta “behaves” 
epidemiologically like pre-eclampsia. 
However, most relevant studies have not shown either increased BMI or diabetes to increase the 
risk of retained placenta as these factors do for pre-eclampsia13,29,37,44,69. Likewise the possibly 
increased risk of retained placenta in populations of European genetic descent is contrary to the 
suggested decreased risk of pre-eclampsia in this population109. 
Delivery-related variables such as induction of labor, epidural use and instrumental delivery 
were either not significantly or only weakly associated to retained placenta in both Study I and 
II. These variables have been associated to retained placenta in other studies as well but may, 
despite statistical adjustments, represent residual confounding and reflect other causal factors 
such as augmented or prolonged labor and preterm birth.  
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7.1.5 Placental underperfusion and oxidative stress  
To my knowledge there are no previous studies on any aspect of the molecular biology of 
retained placenta. Study III was therefore the first to investigate the hypothesis of increased 
oxidative stress and inflammation in retained placenta. The results suggest that antioxidative 
defense capacity may be decreased, although a larger sample would be needed to state this more 
conclusively. However, the results were consistent in that the same pattern of decreased 
expression of GPX1 protein and somewhat increased expression of GPX1 mRNA was seen in 
both peripheral and periumbilical samples of retained placentas. If these results were to be 
supported in larger studies, what we might be seeing is either a posttranslational modification 
that decreases effective antioxidative capacity despite an upregulated gene expression, or the 
effect of negative feedback, with high mRNA expression in response to low or depleted GPX1 
protein. Although decreased GPX1 concentrations cannot confidently be associated to retained 
placenta in this study it is notable that low GPX protein expression and GPX activity has been 
associated to pre-eclampsia and fetal growth restriction74-76.   
It is also interesting that retained placenta was significantly associated to low values of GPX1 
protein. The categorical analysis of GPX1 in relation to retained placenta is informative since 
the distributions of GPX1 concentrations were not normal either among retained or non-retained 
placentas. Biochemical data in humans is often skewed to the left with a preponderance of low 
or normal values and a tail of higher values signaling disease. It may be that this similar pattern, 
seen in retained placenta in relation to GPX1, signals an impaired placental capacity to respond 
to oxidative stress, low values in this case signaling disease (Figure 7). This theory has been put 
forward for pre-eclampsia in relation to antioxidative defense capacity75. 
Study IV found an association between retained placenta and histological signs of maternal 
underperfusion which was new as were characteristics of oblong shape and decreased surface 
area found in retained placenta. These three features have previously been associated to pre-
eclampsia and fetal growth restriction100. Decreased size, aberrant placental shape as well as the 
development of accessory lobes, which were also more common among retained placentas in 
our study, are hypothesized to result from implantation into an area of the uterine cavity with 
poor perfusion65,110. Markers of maternal placental underperfusion likewise reflect decreased 
perfusion of the placenta (as opposed to low perfusion to the fetus due to abnormalities of the 
umbilical cord)110. 
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Figure 7 
Distribution of GPX1 values in peripheral samples of retained and non-retained placentas in 
Study III with superimposed line showing hypothetical normal GPX1 response to labor which may 
be absent or depleted in cases of retained placenta 
 
7.1.6 Inflammation 
Study III did not support a role for increased inflammation in retained placenta mediated by the 
NFκB/IκBα pathway. Likewise Study IV found no histological signs of increased acute 
inflammation in the placenta, although chorioamnionitis was a common finding among both 
retained and non-retained placentas. PROM was not associated to retained placenta in Study I 
and weakly so in Study II. Fever during delivery was not associated to retained placenta in 
Study I. Other studies have likewise found PROM to be a weak risk factor for retained 
placenta4,27,29,37,69. However, PROM and fever can at best only be considered proxy variables 
for infection and NFκB is only an indirect marker of inflammation. Whereas this thesis found 
no clear support for inflammation as an agent in the development of retained placenta, either at 
the epidemiological or at the molecular level, further studies are needed to draw any substantial 
conclusions on the role of inflammation in this disorder. 
Normal GPX1 response to labor 
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7.1.7 The relation to placenta accreta  
Study IV found that retained placenta had histological similarities to placenta accreta in that the 
incidence of BPMF was significantly increased and that cases of focal placenta accreta were 
numerically, although statistically non-significantly, overrepresented among retained placentas. 
The great majority of retained placentas, however, had no BPMF and a wholly intact decidua in 
the samples that were analyzed. Since the whole placental surface was not studied, focally 
accretic sections may have been missed, despite the fact that macroscopically disrupted 
placental areas were sampled. This leaves the question of the relation of retained placenta to 
placenta accreta unresolved. 
Placenta accreta and retained placenta seem to share risk factors related to previous injury to the 
endometrium. Study I distinguished, to the extent possible, between previous miscarriage and 
induced abortion, as well as the surgical intervention, which in Sweden is vacuum aspiration, 
used in a minority of these pregnancies. The study indicated that previous miscarriage and 
induced abortion were significantly related to retained placenta while vacuum aspiration was 
not an independent risk factor in itself. Other studies have likewise shown an association 
primarily to previous induced abortion4,27. Previous surgical treatment for miscarriage or 
abortion is however a variable that is incompletely registered in Swedish obstetric medical 
records which may affect analysis. Some studies have shown an association to previous 
dilatation and curettage (D&C)41,42. Complicating comparisons across studies is the fact that 
most countries no longer use D&C, which represents a sharper trauma to the uterine lining and 
is likely to increase the risk of postoperative intrauterine adhesions111. However, it may be 
telling that an association has been found to this more traumatic form of treatment. Although 
cesarean section was not a risk factor in our first study it has been shown to be a risk factor in 
several other studies27,37,44. Previous retained placenta was a risk factor in Study I as well as in 
earlier studies13,42,107. Postpartum D&C for retained placental products was likely performed in 
some of these study groups but it is very rarely performed in Sweden. It is possible therefore 
that this risk factor reflects different etiologies in different studies: either an initial 
predisposition for retained placenta or previous damage to the uterine wall with subsequent 
increased placental attachment.  
Damage to the uterine lining in a previous pregnancy will probably not alter biological factors 
that determine the risk of retained placenta, but may affect the implantation site for future 
pregnancies. This may result, like it does in cases of placenta accreta, in increased placental 
attachment because of an absent or abnormal decidual transformation of the endometrium. So 
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although the absence of decidua does not seem to affect the majority of cases of retained 
placenta it is possible that a portion of cases can be explained by focally damaged endometrium, 
poor decidual development and compensatory placental attachment as reflected by increased 
BPMF and focal placenta accreta.  
 PATHOPHYSIOLOGICAL MODELS FOR RETAINED PLACENTA 
7.2.1 Risk profiles for retained placenta 
Placing the results of this research project into the context of what is currently known about 
retained placenta, I would like to go back to the idea of two different etiological risk profiles for 
retained placenta: one representing an association to other placental disorders with reduced 
placental perfusion and one representing previous injury to the uterine lining. The results shown 
in this project indicate an epidemiological association between retained placenta and defective 
placentation disorders, supported in part by signs of decreased antioxidative capacity and 
placental perfusion at the molecular and histological level. This, together with the 
epidemiological patterns that retained placenta shows in relation to maternal age, parity, risk of 
repetition and familial clustering suggests that retained placenta has molecular, immunological 
and perhaps genetic etiological components. These may predispose to the development of 
retained placenta already at implantation, carry forward into the next pregnancy and perhaps 
into the next generation. On the other hand, interventions that affect the endometrial lining such 
as D&C after terminated pregnancy or delivery and cesarean section may increase the risk of 
retained placenta by disrupting normal decidual development and increasing attachment at 
implantation in the next pregnancy. Based on the strength of the associations this is probably the 
less common etiology. 
I also suggest that prolonged augmented labor with oxytocin increases the risk of retained 
placenta, possibly because of the stress that this exposure incurs on the contractile apparatus and 
oxygenation of the placenta, something which then impedes normal placental release. Suggested 
increases in incidence of retained placenta, perhaps particularly so in developing countries, and 
globally differing rates may be due both to increases in D&C and cesarean section rates but also 
to the increasing use of oxytocin for labor augmentation. 
7.2.2 Too deep or too shallow placentation? 
If retained placenta originates at placentation it may, as discussed above, occur as a result of 
two unrelated processes, one resulting in increased placental attachment, the other in deficient, 
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or too shallow, placentation. A more symbiotic model is that these two, seemingly opposite, 
placental patterns are themselves related and may as a result take on a similar clinical 
presentation in the third stage of labor. Some studies have indicated that this may be the case. 
Placenta accreta has been shown to present with reduced spiral artery remodeling, the 
pathognomonic pattern of pre-eclampsia60,112. Placental weight and spiral artery remodeling has 
been shown to be reduced in placentas with increased BPMF, a characteristic trait of placenta 
accreta59. A study from as early as 1987 presented the hypothesis that accretic placentation 
occurred in response to an initial incomplete or shallow placentation113. In this combined 
hypothetical model, placentas predisposed to become retained would be more vulnerable to 
oxidative stress irrespective of etiology. Prolonged oxytocin exposure which saturates the 
contractile capacity of the myometrium may then exacerbate an underlying heightened risk for 
retained placenta (Figure 8). 
 
Figure 8 
Schematic model of etiology of retained placenta and association to defective placentation 
disorders, placenta accreta and augmented labor
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8 CONCLUSIONS 
 Prolonged augmented labor by oxytocin is associated to an increased risk of retained 
placenta. 
 
 Retained placenta is associated to postpartum hemorrhage, in particular severe and very 
severe postpartum hemorrhage. 
 
 Optimal timing till manual delivery of the placenta is difficult to assess in a working 
clinical setting and must be guided by individual assessment. 
 
 Defective placentation disorders i.e. pre-eclampsia, preterm birth, SGA birth, stillbirth 
as well as a history of recurrent miscarriage are associated to retained placenta. 
 
 In regard to maternal age, parity and risk of recurrence retained placenta shows 
epidemiological patterns that are similar to those seen in pre-eclampsia. 
 
 The protein expression of GPX1, an antioxidative enzyme, may be decreased in retained 
placenta but this needs to be validated in a larger study. 
 
 Histologically, retained placenta shows no signs of increased placental inflammation 
and retained placental tissue shows no significant increase in NFκB/IκBα mRNA 
expression that would reflect activation of inflammatory pathways. 
 
 Retained placenta ressembles pre-eclampsia and other defective placentation disorders 
in regard to placental shape, size and histological signs of maternal placental 
underperfusion. 
 
 Features of increased placental attachment are overrepresented in retained placentas 
which may suggest a pathophysiologial association to placenta accreta. The majority of 
retained placentas however show no signs of increased placental attachment which 
indicates that retained placenta and placenta accreta are separate disorders. 
 
 In summary, retained placenta is epidemiologically associated to defective placentation 
disorders something which is supported in part by signs of decreased antioxidative 
capacity in the placenta and increased histological signs of maternal placental 
underperfusion. 
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9 CLINICAL AND SCIENTIFIC IMPLICATIONS 
 IMPLICATIONS FOR CLINICAL PRACTICE 
Awareness of risk factors for retained placenta can help to identify women at heightened risk 
and subsequent risk of serious hemorrhage and should guide clinical practice.  
 The risk of retained placenta should be assessed in routine obstetric history. In particular 
a history of retained placenta in a woman giving birth prior to 37 weeks should lead to 
heightened awareness. This risk level should be increased if the pregnancy is 
complicated by pre-eclampsia, fetal growth restriction or stillbirth and if there is a 
history of previous cesarean section. During delivery, prolonged labor augmentation by 
oxytocin should be compounded to this risk profile.  
 
 The level of predicted risk should guide in what setting a woman delivers, whether a 
physician should be present during the third stage and whether preparatory measures are 
taken for manual removal of the placenta. 
 
 The increased risk of retained placenta associated to augmented labor and cesarean 
section, delivery-related interventions that are to some extent avoidable, should be 
weighed in the harm-benefit calculation made before they are used in obstetric practice. 
 IMPLICATIONS FOR THE RESEARCH FIELD: QUESTIONS THAT REMAIN 
There is still a lack of research about retained placenta which is a concern given how serious the 
disorder is. Further research should be perfomed based on the platform of what is now known. 
What is most lacking are studies exploring the pathophysiology of retained placenta: studies in 
molecular biology, immunochemistry and histology that might identify genetic, immunological 
or molecular features as well as histological characteristics specific to retained placenta.  
 
 In relation to oxidative stress: a broader analysis of antioxidative defense systems and 
products of oxidative stress in retained placenta at the gene, protein and enzyme activity 
level. 
 
 In relation to disorders of defective placentation: an analysis of molecular markers 
associated to pre-eclampsia and fetal growth restriction in retained placentas. 
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 In relation to histology: a complete analysis of the placental bed in retained placenta 
compared to non-retained placenta as well as placentas delivered manually at cesarean 
section; myometrial biopsy sampling at manual removal of the placenta to assess the 
degree of spiral artery remodeling in retained placenta compared to non-retained 
placentas.  
Knowledge of the pathophysiology of this disorder and its relationship to other pregnancy-
related diseases could eventually be instrumental in its prevention or in its less invasive 
treatment. This is of paramount importance to the women who are most vulnerable to the 
consequences of postpartum hemorrhage, namely women in poor countries without access to 
modern obstetric emergency care. 
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10 POPULÄRVETENSKAPLIG SAMMANFATTNING  
Placentaretention (kvarhållen moderkaka) innebär att placentan inte lossnar spontant inom 30 
minuter efter barnets födelse och uppstår vid 2-3% av alla förlossningar. Det är en av de 
främsta orsakerna till allvarlig blödning efter förlossning och i områden utan tillgång till 
sjukhusvård är tillståndet ofta dödligt. Behandlingen, manuell placentalösning, utsätter den 
nyförlösta kvinnan för sövningsrisken och en ökad risk för infektion i livmodern. Orsaken 
bakom placentaretention är inte känd. Detta forskningsprojekt genomfördes för att tydliggöra 
riskfaktorer för placentaretention, utvärdera sambandet mellan placentaretention och andra 
graviditetssjukdomar och undersöka om det finns molekylära eller vävnadsstrukturella 
utmärkande drag för tillståndet.  
Studie I, en fall-kontroll studie, bekräftade att placentaretention innebär en kraftigt ökat risk 
för allvarlig blödning efter förlossning. Studien fann även ett samband mellan 
placentaretention och långvarig användning av oxytocin för värkstimulering under 
förlossning. Preeklampsi, förtidsbörd och tidigare missfall var också riskfaktorer för 
placentaretention i studien. Dessa tillstånd är, tillsammans med dödföddhet och 
tillväxthämning, tillstånd med så kallad ”defekt placentation”, där den ursprungliga 
infästningen i livmodern är rubbad. Blodförsörjningen i placentavävnaden är försämrad vid 
dessa tillstånd vilket kan ses i vävnaden som ökad syreorsakad stress på molekylär nivå och 
genom strukturella tecken till dålig blodförsörjning på mikroskopisk nivå. Studie II, en stor 
populationsbaserad studie, fann att alla dessa tillstånd var kopplade till placentaretention. 
I Studie III och IV samlades kvarhållna och icke-kvarhållna placentor in efter förlossningen 
för vävnadsanalys. Studie III fann en tendens till lägre kapacitet att försvara sig mot 
syreorsakad stress i placentor som varit kvarhållna jämfört med placentor som inte varit 
kvarhållna. Studie IV fann att kvarhållna placentor var mindre till ytan, mer avlånga i formen 
och visade fler strukturella tecken till dålig blodförsörjning i vävnaden jämfört med icke-
kvarhållna placentor. Både biokemiskt och strukturellt fanns det alltså likheter mellan 
placentor som varit kvarhållna och placentor där graviditeten komplicerats av tillstånd med 
defekt placentation.  
Sammanfattningsvis är placentaretention epidemiologiskt kopplad till en grupp andra 
placentära sjukdomar med ursprunglig defekt placentation. De utmärkande molekylära och 
vävnadsstrukturella dragen i placentan vid dessa tillstånd kan i viss grad också ses vid 
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placentaretention vilket stärker sambandet. Kunskap om riskfaktorer för placentaretention bör 
vägas in i hur sjukvårdspersonal behandlar kvinnor efter förlossningen. Att förstå orsaken 
bakom placentaretention är nästa steg mot att kunna förebygga och behandla ett tillstånd som 
framför allt för kvinnor i låginkomstländer innebär en livshotande risk. 
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12 APPENDIX: HISTOLOGICAL DEFINITIONS  
Artheriolopathy: Fibrinoid necrosis of the spiral artery wall, often with dilation of the vessels, presence 
of acute atherosis and lumen thrombosis.  
Basal plate myometrial fibers: Myometrial smooth muscle cells at the maternal floor with intervening 
decidua.  
Chorangiosis : vascular hyperplasia in the terminal chorionic villi and defined according to Altshuler´s 
criteria 114.  
Chorionitis/subchorionitis: presence of neutrophils in the chorion or subchorion. 
Chorioamnionitis: expansion into the chorioamniotic mesoderm and/or amnion. 
Chronic villitis: Presence of lymphocytes with or without histiocytes in the stroma of placental villi.   
Fetal thrombosis: Thrombosis in the vessels of the umbilical cord, chorionic plate or stem villi. 
Funicitis: Inflammation as defined above extending into Wharton´s jelly.   
Grouped multinucleated trophoblastic cells: Trophoblastic cells with three or more clustered 
trophoblasts in the decidua each with three or more nuclei 115.  
Placental abruption: Presence of a retroplacental hematoma was recorded as suggestive of the disorder. 
Placenta accreta:  Absence of intervening decidua between the chorionic plate and the myometrium. 
Placental infarction:  ischemic necrosis of the villi. Fetal thrombosis was defined as thrombosis in the 
vessels of the umbilical cord, chorionic plate or stem villi.  
Placental septal cysts: Cysts within the septa that separate the cotyledons of the placenta. 
Syncytial knots: >10 aggregated syncytical nuclei at the surface of the terminal villi 34. 
Umbilical vasculitis: Presence of neutrophils in the walls of the umbilical cord.  
Villous agglutination: Syncytial knotting with collapse of the villous space. 
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